Saw this today as I was searching on 3cl Protease Inhibitor

Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19 - Tue, October 11, 2022 at 8:00 AM

https://www.yahoo.com/now/cocrystal-pharma-se...00441.html

The stock really took a beating since uplisting to the NASDAQ in 2018. Went from about $100 a share to to $2.50, about a 97% loss. The only other bio stock I've seen that did much worse is IBIO that dropped more than that in less than 1/2 the time.

They both have more in common. Both just did a reverse split. Both have little to no revenue. Both have little to nothing in clinical trials except Cocrystal does have 1 thing in Phase IIA. They both have a market cap of 20 something million.

Now compare that to Todos that has a lower market cap who revenues this year may even exceed their market cap.

Compare Todos many real opportunities with IBIO and COCP which have none and one respectively.

COCP isn't even in Phase I with their Covid Antivirals.
https://www.cocrystalpharma.com/development-p...e/overview

Perspective, it's a wonderful thing